Aurobindo Pharma Limited has informed the Exchange about General Updates
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Midcap 150 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The US FDA inspected Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of Aurobindo Pharma, located in Naidupeta Mandal, SPSR Nellore District, Andhra Pradesh, from December 8 to December 17, 2025. At the end of the inspection, the FDA issued a Form 483 with 5 observations. The unit has now received an Establishment Inspection Report (EIR) classifying the facility as 'Voluntary Action Indicated' (VAI), and the inspection has been officially closed. A VAI classification means the FDA did not find significant regulatory violations requiring mandatory action, though the observations should be voluntarily addressed.
This is a positive development for Aurobindo Pharma as VAI is a favorable outcome that removes near-term regulatory overhang on this facility, though the 5 observations remain to be voluntarily addressed. The closure allows the unit to continue supplying the US market without restrictions.